In 2024, our laboratory achieved CLIA and CAP certification, enabling the regulated clinical deployment of our proteomics platforms and accelerating the translation of deep proteome measurement into real-world diagnostics.
CLIA and CAP Certification Approved for Our Clinical Proteomics Laboratory
In 2024, Complete Omics achieved a major milestone in the clinical translation of its technologies with the successful certification of its laboratory under the Clinical Laboratory Improvement Amendments (CLIA) program and accreditation by the College of American Pathologists. These approvals represent a critical step in transforming the company’s advanced proteomics technologies into deployable clinical testing platforms.
CLIA certification is the regulatory framework that governs clinical laboratory testing in the United States, ensuring that laboratories performing diagnostic tests meet rigorous standards for analytical validity, quality control, and operational reliability. CAP accreditation further validates laboratory performance through one of the most stringent peer-review inspection programs in clinical diagnostics.
Together, these certifications establish Complete Omics’ laboratory as a high-complexity clinical testing environment, capable of supporting regulated diagnostic assays and large-scale clinical studies.
Enabling Clinical Deployment of Proteomics Technologies
The regulatory approval allows Complete Omics to begin translating its core technology platforms—including Complete360® and Valid-NEO®—into clinical-grade testing services.
This infrastructure enables the company to support a broad range of applications, including:
- molecular diagnostics and biomarker testing
- early disease detection research
- therapeutic monitoring and precision medicine studies
- pharmaceutical and biotechnology collaborations
- large-scale multi-omics clinical cohort analysis
By operating within a CLIA-certified and CAP-accredited laboratory environment, the company can ensure that its proteomics assays meet the stringent requirements necessary for clinical reliability and regulatory compliance.
From Research Technology to Clinical Infrastructure
Proteomics has historically been viewed primarily as a research tool due to challenges related to reproducibility, scalability, and regulatory compliance. Achieving CLIA and CAP approval marks a major step toward addressing these challenges and establishing proteomics as a clinically deployable molecular measurement technology.
For Complete Omics, this milestone reflects years of engineering work across multiple layers of the technology stack, including:
- optimized sample preparation workflows
- standardized assay development protocols
- high-performance mass spectrometry instrumentation
- rigorous quality control systems
- scalable data processing pipelines
Together, these systems enable the reproducible measurement of large numbers of proteins across clinical samples with the consistency required for regulated diagnostic testing.
A New Phase of Platform Development
The 2024 regulatory milestone marks the beginning of a new phase for Complete Omics: expanding the application of its technologies from research environments into real-world healthcare settings.
With its clinical laboratory infrastructure now in place, the company is positioned to deploy its proteomics platforms to support precision diagnostics, therapeutic development, and large-scale molecular medicine programs.
As clinical proteomics continues to mature, the ability to measure thousands of proteins across patient samples may become an increasingly important component of the molecular toolkit used to understand, detect, and treat human disease.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.